How Much Does a GLP-1 Cost Per Year in 2026?
GLP-1 annual cost at a glance (May 2026)
| Drug | Cheapest cash-pay / year | Typical maintenance / year | Insured + Savings Card / year |
|---|---|---|---|
| Wegovy semaglutide injection | $4,188 | $4,188 | $300 |
| Wegovy oral 25 mg oral semaglutide | $1,788 | $1,788 | $300 |
| Zepbound tirzepatide injection | $4,788 | $5,388 | $300 |
| Foundayo orforglipron (oral) | $1,788 | $3,588 | $300 |
| Mounjaro tirzepatide injection | $5,988 | $5,988 | $300 |
| Ozempic semaglutide injection | $4,788 | $4,788 | $300 |
| Saxenda liraglutide injection | N/A | N/A | $300 |
All figures are monthly cash-pay or covered-copay × 12. Year-1 is often cheaper for drugs with dose ramps (Wegovy, Foundayo, Zepbound, oral Wegovy) — see the per-drug detail below for the ramp math. Every monthly number is the same one used by our calculator and traces to /sources per our editorial standard.
3-year cumulative cost: cheapest realistic path per drug
| Drug | 1 year | 3 years | 5 years |
|---|---|---|---|
| Foundayo (0.8 mg) | $1,788 | $5,364 | $8,940 |
| Wegovy oral 25 mg (1.5/4 mg titration) | $1,788 | $5,364 | $8,940 |
| Foundayo (5.5 mg+ maintenance) | $3,588 | $10,764 | $17,940 |
| Wegovy injection (NovoCare) | $4,188 | $12,564 | $20,940 |
| Zepbound LillyDirect (5 mg) | $4,788 | $14,364 | $23,940 |
| Zepbound LillyDirect (7.5–15 mg) | $5,388 | $16,164 | $26,940 |
| Any drug, insured + Savings Card | $300 | $900 | $1,500 |
| Cash retail (Wegovy/Saxenda WAC) | $16,188 | $48,564 | $80,940 |
The savings-card row assumes the card is renewed every year and your insurance keeps the drug on formulary at the same tier. Real-world: many cards cap at $1,300–$1,800/year, and formulary changes at the new plan year can move you to a different tier. Re-check eligibility each January.
Year-1 vs year-2+ math, per drug
Wegovy (semaglutide injection)
Year 1 (titration): First 2 months of 0.25 mg/0.5 mg titration: $199 via NovoCare (through Jun 30, 2026). Then $349 for the 1 mg → 2.4 mg maintenance climb.
Year 2+ (steady-state): $349/mo NovoCare ongoing for the 2.4 mg maintenance dose. The 7.2 mg HD dose is also $349 ongoing after the same 2-month $199 promotional window.
Wegovy oral 25 mg (oral semaglutide)
Year 1 (titration): 1.5 mg and 4 mg titration doses are $149/mo via NovoCare. The 4 mg promotional discount runs through Aug 31, 2026 - then $199/mo for 4 mg.
Year 2+ (steady-state): 25 mg maintenance dose NovoCare cash-pay pricing tracks the injection ($349). Lower titration doses (1.5 mg, 4 mg) stay at $149 through the promotional period.
Zepbound (tirzepatide injection)
Year 1 (titration): LillyDirect vial dose ramp: 2.5 mg starter at $299/mo, 5 mg at $399/mo, 7.5 mg–15 mg at $449/mo (all within the 45-day refill window).
Year 2+ (steady-state): $399–$449/mo LillyDirect vials at the typical 5 mg–15 mg maintenance range. Out-of-refill-window pricing jumps to $599–$1,049 for higher doses.
Foundayo (orforglipron (oral))
Year 1 (titration): LillyDirect dose ramp: 0.8 mg lowest dose at $149/mo, 2.5 mg at $199/mo, 5.5 mg+ at $299/mo (within the 45-day refill window). Medicare Part D-eligible patients can pay $50/mo from July 1, 2026.
Year 2+ (steady-state): $299/mo LillyDirect for the typical 5.5+ mg maintenance range. The 14.5 / 17.2 mg highest doses move to $349/mo if the refill window lapses.
Mounjaro (tirzepatide injection)
Year 1 (titration): No LillyDirect self-pay program. Cash-pay floor is branded telehealth ($499/mo) or compounded tirzepatide where still available ($299/mo).
Year 2+ (steady-state): Same as year 1 - Mounjaro pricing does not change at maintenance. For type 2 diabetes patients with commercial insurance + Mounjaro Savings Card: $25/fill, $300/yr.
Ozempic (semaglutide injection)
Year 1 (titration): No NovoCare self-pay program. Cash-pay floor is branded telehealth (~$399/mo) or compounded semaglutide ($199/mo where still available).
Year 2+ (steady-state): Same as year 1 - Ozempic pricing does not change at maintenance. For T2D patients with commercial insurance + Ozempic Savings Card: $0–$25/fill, $0–$300/yr.
Saxenda (liraglutide injection)
Year 1 (titration): No NovoCare self-pay program. Branded telehealth around $399/mo. With insurance + Saxenda Savings Card: $25/fill.
Year 2+ (steady-state): Same as year 1 - Saxenda is a daily injection; cost is constant. At $1,349 list price with weaker efficacy than newer drugs, Saxenda is rarely the right value in 2026 except where insurance specifically prefers it.
Why annual cost is the right framing for GLP-1s
Phase 3 follow-up data is consistent: stopping a GLP-1 leads to substantial weight regain over 6–12 months (STEP-4 reported about 11.6% mean regain within a year of semaglutide withdrawal). Most realistic treatment courses are multi-year, not multi-month, which is why the annual cost - and especially the year-2+ steady-state cost - is usually more important than the year-1 sticker number. The lowest-cost initial path is sometimes not the lowest-cost multi-year path, especially once you account for dose escalation and the difference in efficacy across drugs.
Frequently asked questions
How much does a GLP-1 cost per year in 2026 on the cheapest legitimate path?
It depends on the drug, but the cheapest branded GLP-1 cash-pay path in May 2026 is Foundayo (orforglipron) or oral Wegovy 25 mg titration doses at $149/month, which is about $1,788 per year. Foundayo's higher doses go to $299/month ($3,588/year) and Wegovy injection goes to $349/month at NovoCare standard ongoing ($4188/year). Zepbound LillyDirect maintenance runs $399–$449/month ($4,788–$5,388/year). With commercial insurance plus a manufacturer savings card the annual out-of-pocket can drop to $25/month × 12 = $300/year for the weight-loss-indicated drugs (Wegovy, Zepbound, Foundayo).
Is year 1 cheaper than year 2 and beyond?
For Wegovy injection, Wegovy oral 25 mg, Zepbound, and Foundayo, year 1 is meaningfully different from steady state because of titration. You spend less in the first 2–6 months at lower doses, then ramp into the maintenance dose. Specifically: Wegovy injection NovoCare runs $199/mo for the first 2 months of 0.25/0.5 mg through Jun 30, 2026, then $349/mo. Foundayo starts at $149/mo for 0.8 mg, $199 for 2.5 mg, and $299+ for 5.5 mg and up. Zepbound is $299 for the 2.5 mg starter, $399 for 5 mg, and $449 for 7.5 mg+ on LillyDirect. Year 2+ assumes a stable maintenance dose, so cost is just the maintenance monthly × 12.
What does a 3-year course of Wegovy actually cost?
Direct manufacturer self-pay path: about $12,564 over 3 years at NovoCare ($349/month × 36). With commercial insurance and the Wegovy Savings Card at $25/fill, three years runs roughly $900. On the Novo Nordisk subscription program through Hims/Ro/LifeMD/WeightWatchers/Sesame at the $249/mo 12-month tier, three years is $8,964. List price would be $1,349 × 36 = $48,564, but almost no one pays that.
What does a 3-year course of Zepbound actually cost?
On LillyDirect self-pay vials at typical maintenance pricing: about $14,400 over 3 years ($399/month × 36) on 5 mg, or $16,164 ($449/month × 36) on higher doses. Year 1 is cheaper because of the $299/month starter dose. With commercial insurance + the Zepbound Savings Card at $25/fill, three years runs roughly $900. The Zepbound Savings Card also has the non-covered KwikPen path at $299–$449/month for commercially-insured patients whose plan excludes Zepbound, which extends to about $10,764–$16,164 over 3 years.
What does a 3-year course of Foundayo (orforglipron) cost?
Direct manufacturer self-pay path: about $5,364 over 3 years if you stay at the 0.8 mg dose ($149/month × 36), or about $10,764 at the typical 5.5 mg+ maintenance dose ($299/month × 36). Year 1 is meaningfully cheaper due to the dose ramp. With commercial insurance + Foundayo Savings Card at $25/fill: about $900 over 3 years. Medicare Part D-eligible patients can pay $50/month starting July 1, 2026 — that's about $1,800 over 3 years.
Why is the manufacturer self-pay so much cheaper than the list price?
Eli Lilly and Novo Nordisk both run direct-to-patient programs (LillyDirect, NovoCare) priced well below their drugs' Wholesale Acquisition Cost (WAC). The structural reason is rebate dynamics: list prices are a negotiation anchor for PBM rebates, and rebates flow back to insurers and PBMs, not patients. Manufacturer direct-to-patient programs bypass the rebate chain entirely, so the cash-pay number is closer to the manufacturer's real net selling price than the list price is.
Do I really need to stay on a GLP-1 forever?
Clinical trials consistently show that stopping a GLP-1 leads to substantial weight regain over the following 6–12 months. STEP-4 (semaglutide) showed an average of about 11.6% weight regain within 1 year of stopping. So the cost-per-year framing matters because most realistic treatment courses are multi-year, not 3–6 months. The longer the planned course, the more value the cheapest steady-state path provides — which is why year 2+ pricing is often more important than year 1.
Does insurance get more expensive in year 2?
For most plans, your copay stays the same year over year as long as the drug stays on formulary and your savings card is renewed. The two real year-2 cost surprises are: (1) the manufacturer savings card hits its annual cap (most cards cap at $1,300–$1,800/year) — after the cap, you pay the plan-set copay without the discount; (2) your insurer drops the drug from formulary or moves it to a higher tier at the next plan year. Re-check your plan documents each January.
What's the cheapest realistic 1-year path for someone with no insurance?
Foundayo at $149/month ($1,788/year) or Wegovy oral 25 mg at $149/month ($1,788/year) for titration doses are the cheapest branded FDA-approved GLP-1 cash-pay paths in May 2026. Both lock in the lowest sticker price through their respective manufacturer direct programs (LillyDirect and NovoCare). The trade-off versus higher-efficacy options (Zepbound LillyDirect starter at $299, ~$3,588/year): Zepbound's 22.5% trial weight loss vs Foundayo's 14.7% / oral Wegovy's 13.6%. For maximum total weight loss per dollar spent over a 1-year course, Zepbound usually wins despite a higher annual outlay.
What about Medicare or Medicaid? What does a year cost there?
Medicare: weight-loss-only GLP-1s are statutorily excluded from Part D coverage. Wegovy gained limited Part D coverage in March 2024 for established cardiovascular disease patients — annual cost there is typically $360–$1,200 in Part D copays. Foundayo announced a $50/month Medicare-eligible tier starting July 1, 2026 — $600/year. Without those carve-outs, Medicare beneficiaries pay LillyDirect or NovoCare cash-pay (same as anyone without insurance). Medicaid varies dramatically by state: most state Medicaid programs cover GLP-1s for type 2 diabetes only, so the Mounjaro/Ozempic pathway is the realistic Medicaid route at ~$0–$50/year. A handful of states cover Wegovy or Zepbound for weight loss under strict prior auth.
Related guides
Stay ahead of every GLP-1 development
We'll email you when something actually matters: new FDA approvals (Foundayo, CagriSema, retatrutide), pricing drops at LillyDirect/NovoCare, telehealth deals, clinical trial results, FDA recalls, and insurance policy changes. ~1-2 emails/month. No filler.